Approval Through FDA’s De Novo Pathway: A Major Accomplishment! featuring Osteoboost
/
DateApr 16 2025
In January 2024, Osteoboost achieved a notable regulatory milestone by receiving De Novo classification from the U.S. Food and Drug Administration (FDA). This designation is... Read More →



















